Wide Ranks

BDRX

Biodexa Pharmaceuticals plc

4.93

Top Statistics
Market Cap 2 M Forward PE -2.46 Revenue Growth 0.00 %
Current Ratio 2.16 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2774.30 Enterprise / Revenue 215325.89 Price To Sales Trailing12 Months 34.50
Profitability
Profit Margins 0.00 % Operating Margins -7931.33 %
Balance Sheet
Total Cash 5 M Total Cash Per Share 0.0010 Total Debt 382000
Total Debt To Equity 4.38 Current Ratio 2.16 Book Value Per Share 24.07
All Measures
Short Ratio 4.00 % Message Board Id finmb_278298574 Shares Short Prior Month 27649
Return On Equity -0.9723 City Cardiff Uuid 77d68f67-48f8-35fb-8abb-8876c307ccfa
Previous Close 4.80 First Trade Date Epoch Utc 1 B Book Value 24.07
Beta 1.44 Total Debt 382000 Volume 39012
Price To Book 0.2048 Last Split Date 1 B Fifty Two Week Low 3.50
Total Cash Per Share 0.0010 Total Revenue 83000 Shares Short Previous Month Date 1 B
Target Median Price 156.43 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -7931.33 % Target Mean Price 156.43 Net Income To Common -6819000
Short Percent Of Float 0.0275 Implied Shares Outstanding 4 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 634700 Average Volume10days 634700
Total Cash 5 M Next Fiscal Year End 1 B Revenue Per Share 0.4350
Held Percent Insiders 0.1016 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 4.80 Target Low Price 156.43
Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.85 Open 4.85
Free Cashflow -4072875 Dividend Yield 0.00 % Return On Assets -0.3752
Time Zone Short Name EST Trailing Eps -75.43 Day Low 4.76
Address1 1 Caspian Point Shares Outstanding 580840 Price Hint 4
Target High Price 156.43 Website https://www.biodexapharma.com 52 Week Change -0.9455
Average Volume 259956 Recommendation Key none Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 216.10 % Last Split Factor 1:25
Regular Market Day High 5.17 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 4.38 Fifty Two Week High 113.00 Day High 5.17
Shares Short 15998 Regular Market Open 4.85 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 215325.89 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0275 Operating Cashflow -7752000 Currency USD
Time Zone Full Name America/New_York Market Cap 2 M Is_nasdaq_100 False
Zip CF10 4DQ Quote Type EQUITY Industry Biotechnology
Long Name Biodexa Pharmaceuticals Plc Regular Market Day Low 4.76 Held Percent Institutions 0.3525
Current Price 4.93 Address2 Caspian Way Enterprise To Ebitda -2774.30
Financial Currency GBP Current Ratio 2.16 Gross Margins 174.70 %
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United Kingdom
Float Shares 2 B Two Hundred Day Average 19.32 Enterprise Value 17 B
Price To Sales Trailing12 Months 34.50 Forward PE -2.46 Regular Market Volume 39012
Ebitda -6442000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain.

Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.

In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.

It has collaboration agreements with Janssen and Melior.

The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023.

Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.